Nicolet Advisory Services LLC Lowers Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Nicolet Advisory Services LLC decreased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.6% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,117 shares of the medical research company’s stock after selling 103 shares during the quarter. Nicolet Advisory Services LLC’s holdings in Thermo Fisher Scientific were worth $1,148,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. SevenBridge Financial Group LLC increased its stake in shares of Thermo Fisher Scientific by 100.8% during the 4th quarter. SevenBridge Financial Group LLC now owns 1,910 shares of the medical research company’s stock valued at $1,041,000 after acquiring an additional 959 shares during the last quarter. Cynosure Group LLC increased its position in Thermo Fisher Scientific by 189.2% during the fourth quarter. Cynosure Group LLC now owns 4,786 shares of the medical research company’s stock worth $2,490,000 after purchasing an additional 3,131 shares during the last quarter. Bryce Point Capital LLC purchased a new position in Thermo Fisher Scientific during the fourth quarter worth approximately $1,536,000. Huntington National Bank grew its stake in shares of Thermo Fisher Scientific by 1.1% during the 4th quarter. Huntington National Bank now owns 133,780 shares of the medical research company’s stock valued at $69,596,000 after buying an additional 1,405 shares during the period. Finally, RFG Bristol Wealth Advisors LLC acquired a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth $1,729,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the firm’s stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total value of $175,677.00. Following the transaction, the executive vice president now owns 16,363 shares of the company’s stock, valued at $9,582,009.17. This trade represents a 1.80 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Stephen Williamson sold 9,825 shares of the company’s stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total value of $5,753,421.75. Following the transaction, the chief financial officer now directly owns 27,296 shares of the company’s stock, valued at $15,984,264.64. This trade represents a 26.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 23,900 shares of company stock valued at $13,106,062 in the last quarter. Insiders own 0.34% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on TMO. Raymond James reissued an “outperform” rating and set a $667.00 price target (up previously from $650.00) on shares of Thermo Fisher Scientific in a research report on Monday, February 3rd. Sanford C. Bernstein upgraded Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 target price for the company in a report on Friday, January 10th. Morgan Stanley raised their price target on shares of Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an “overweight” rating in a report on Friday, January 31st. Scotiabank boosted their price objective on shares of Thermo Fisher Scientific from $605.00 to $650.00 and gave the stock a “sector perform” rating in a research note on Monday, February 3rd. Finally, Wells Fargo & Company raised their target price on shares of Thermo Fisher Scientific from $660.00 to $680.00 and gave the company an “overweight” rating in a research note on Friday, January 31st. Four investment analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $653.23.

Thermo Fisher Scientific Stock Performance

Shares of TMO opened at $489.25 on Thursday. The firm has a market cap of $184.57 billion, a price-to-earnings ratio of 29.60, a PEG ratio of 2.99 and a beta of 0.79. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. The business’s 50 day moving average is $536.85 and its two-hundred day moving average is $549.69. Thermo Fisher Scientific Inc. has a 52-week low of $475.27 and a 52-week high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. Analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, March 14th. This represents a $1.72 annualized dividend and a yield of 0.35%. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. Thermo Fisher Scientific’s dividend payout ratio is presently 10.41%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.